TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Income Statement
NASDAQ:TNXP - Nasdaq - US8902608392 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.04M | 10.09M | 7.77M | 0.00 | 0.00 | |||
| Cost Of Goods | 7.05M | 7.76M | 4.74M | N/A | N/A | |||
| Gross Profit | 2.99M | 2.33M | 3.03M | N/A | N/A | |||
| Operating Expenses | 75.44M | 80.07M | 121.41M | 112.09M | 92.31M | |||
| Research and Development | 34.55M | 39.97M | 86.66M | 81.88M | 68.84M | |||
| Selling, General, and Administrative Expenses | 40.90M | 40.10M | 34.75M | 30.22M | 23.47M | |||
| Operating Income | -72.45M | -77.74M | -118.38M | -112.09M | -92.31M | |||
| Interest Income/Expense | N/A | N/A | N/A | 1.87M | 30.00K | |||
| Other Income/Expense | 1.57M | 6.67M | 1.72M | N/A | N/A | |||
| Non Recurring Items | -61.05M | -58.96M | N/A | N/A | N/A | |||
| Income Before Taxes | -131.93M | -130.04M | -116.66M | -110.22M | -92.29M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -131.93M | -130.04M | -116.66M | -116.88M | -92.29M | |||
| EBITDA | -69.74M | -74.32M | -114.09M | -110.84M | -92.26M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.96K | -176.60 | -21.93K | -65.30K | -164.80K | |||
| Non GAAP EPS | -1.96K | -2.54K | -27.58K | -81.40K | -166.40K | |||
| Statistics | ||||||||
| Gross Profit Margin | 29.81% | 23.07% | 38.97% | N/A | N/A | |||
| Profit Margin | -1313.87% | -1288.25% | -1501.78% | N/A | N/A | |||
| Operating Profit Margin | -721.51% | -770.20% | -1523.94% | N/A | N/A | |||
All data in USD